RxDoctor Payments Data

Ellen Pan, MD

Ophthalmology · Brooklyn, NYNPI 1003813247

Payments from drug & device makers

$1,919in general payments, 2019–2025

Across 82 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$333
  • Bausch & Lomb Americas Inc.$317
  • Sun Pharmaceutical Industries Inc.$230
  • Alcon$216
  • Novartis$195
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$164
  • plus $464 from 11 others

What the payments were for

  • Food & beverage$1,90299%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,919 in reported general payments places this provider in the 55th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$103,282
Medicare patients
342
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine291$216,444
LumiganBimatoprost318$138,533
CombiganBrimonidine Tartrate/Timolol226$95,698
ProlensaBromfenac Sodium183$69,525
Tobradex StTobramycin/Dexamethasone120$34,575
XiidraLifitegrast45$32,642
Alphagan PBrimonidine Tartrate35$18,725
RocklatanNetarsudil Mesylat/Latanoprost48$16,244
Bepotastine Besilate60$11,118
TyrvayaVarenicline Tartrate17$10,867
Cyclosporine30$10,732
Tobramycin-DexamethasoneTobramycin/Dexamethasone167$10,497
VyzultaLatanoprostene Bunod21$10,335
Restasis MultidoseCyclosporine11$7,146
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol53$6,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose$333$476,546881 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$164$69,525183 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$317$42,97666 claims
Eyevance Pharmaceuticals LLCTobradex St$20$34,575120 claims
Aerie Pharmaceuticals, Inc.Rocklatan$19$16,24448 claims
Oyster Point Pharma, Inc.Tyrvaya$133$10,86717 claims
AlconSimbrinza$216$4,96821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →